[
  {
    "ts": null,
    "headline": "Salesforce Reports Record Second Quarter Fiscal 2026 Results",
    "summary": "SAN FRANCISCO, September 03, 2025--Salesforce Reports Record Second Quarter Fiscal 2026 Results",
    "url": "https://finnhub.io/api/news?id=cd63b24101809bb03272950151373334265f0a5bca8bd003305aaf133af1f30c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756933260,
      "headline": "Salesforce Reports Record Second Quarter Fiscal 2026 Results",
      "id": 136642160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, September 03, 2025--Salesforce Reports Record Second Quarter Fiscal 2026 Results",
      "url": "https://finnhub.io/api/news?id=cd63b24101809bb03272950151373334265f0a5bca8bd003305aaf133af1f30c"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Health care stocks retreated late Wednesday afternoon, with the NYSE Health Care Index down 0.3% and",
    "url": "https://finnhub.io/api/news?id=3653e24500c574626a4d9e61fabdfa98699d8e685e00a07c4cd6ad43d9afb734",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756932775,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 136642161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks retreated late Wednesday afternoon, with the NYSE Health Care Index down 0.3% and",
      "url": "https://finnhub.io/api/news?id=3653e24500c574626a4d9e61fabdfa98699d8e685e00a07c4cd6ad43d9afb734"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Wednesday Afternoon",
    "summary": "Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the H",
    "url": "https://finnhub.io/api/news?id=a345afdc60a5701997e607845e50e8d54536a76165c1cf11e34840c364702bea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756925034,
      "headline": "Sector Update: Health Care Stocks Retreat Wednesday Afternoon",
      "id": 136631173,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the H",
      "url": "https://finnhub.io/api/news?id=a345afdc60a5701997e607845e50e8d54536a76165c1cf11e34840c364702bea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study",
    "summary": "Pfizer (PFE) recently made headlines with Olema Pharmaceuticals announcing a significant clinical trial collaboration, enhancing their portfolio in the treatment of metastatic breast cancer. Over the last quarter, Pfizer's stock moved up by 7%, aligning with broader market trends. This increase may have been driven by the improved Q2 2025 earnings report, which showed significant revenue and net income growth. Additionally, product innovations like the new COVID-19 vaccine approval with...",
    "url": "https://finnhub.io/api/news?id=cac5c4168cd6b720cd7c89c8c6b52351b8e05275a52cc6b37610f0ecffcdaca5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756923911,
      "headline": "Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study",
      "id": 136631174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) recently made headlines with Olema Pharmaceuticals announcing a significant clinical trial collaboration, enhancing their portfolio in the treatment of metastatic breast cancer. Over the last quarter, Pfizer's stock moved up by 7%, aligning with broader market trends. This increase may have been driven by the improved Q2 2025 earnings report, which showed significant revenue and net income growth. Additionally, product innovations like the new COVID-19 vaccine approval with...",
      "url": "https://finnhub.io/api/news?id=cac5c4168cd6b720cd7c89c8c6b52351b8e05275a52cc6b37610f0ecffcdaca5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize",
    "summary": "The company is “dedicated to continuing to provide clear, factual data to the public,” Pfizer Chief Executive Officer Albert Bourla said in the statement, adding that data on Pfizer’s Covid shot has been disclosed in more than 600 peer-reviewed publications.  Bourla also praised Trump’s handling of Operation Warp Speed, which shepherded the development of Covid vaccines, saying the effort “would typically be worthy of the Nobel Peace Prize, given its significant impact.”",
    "url": "https://finnhub.io/api/news?id=00f75ba52457ff645b6793c88bbf5da9ab90e34d883df2a57ae877a196cd7917",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756915117,
      "headline": "Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize",
      "id": 136616967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company is “dedicated to continuing to provide clear, factual data to the public,” Pfizer Chief Executive Officer Albert Bourla said in the statement, adding that data on Pfizer’s Covid shot has been disclosed in more than 600 peer-reviewed publications.  Bourla also praised Trump’s handling of Operation Warp Speed, which shepherded the development of Covid vaccines, saying the effort “would typically be worthy of the Nobel Peace Prize, given its significant impact.”",
      "url": "https://finnhub.io/api/news?id=00f75ba52457ff645b6793c88bbf5da9ab90e34d883df2a57ae877a196cd7917"
    }
  },
  {
    "ts": null,
    "headline": "J&J Gears Up for Some Key New Drug Approvals and Launches",
    "summary": "JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.",
    "url": "https://finnhub.io/api/news?id=a8a5730ba2e501e9314437e189fcd95d6828f4c15c021bbf80055f56dfbe0a9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756911840,
      "headline": "J&J Gears Up for Some Key New Drug Approvals and Launches",
      "id": 136616897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.",
      "url": "https://finnhub.io/api/news?id=a8a5730ba2e501e9314437e189fcd95d6828f4c15c021bbf80055f56dfbe0a9c"
    }
  }
]